Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.
Ahmad Tarhini, MD, PhD
Advertisement
Ahmad Tarhini, MD, PhD, is a tenured senior member of the Departments of Cutaneous Oncology and Immunology, the director of Cutaneous Clinical and Translational Research, and the leader of the Neoadjuvant and Adjuvant Translational Science Program at the Moffitt Cancer Center and Research Institute; as well as a professor of oncologic sciences at the University of South Florida Morsani College of Medicine
Articles by Ahmad Tarhini, MD, PhD
Ahmad A. Tarhini, MD, PhD, discusses findings from the ECOG-ACRIN EA6194 trial of pembrolizumab plus vidutolimod in resectable melanoma.
Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.
Ahmad Tarhini, MD, PhD, discusses the use of high-dose bolus IL-2 with ipilimumab followed by nivolumab in advanced melanoma following prior progression.
Ahmad Tarhini, MD, PhD, discusses a prognostic model evaluating patients with advanced melanoma treated with immune checkpoint inhibitors.
Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.
Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses adjuvant therapy for patients with melanoma.
Advertisement
Latest Updated Articles
Dr. Tarhini Discusses Adjuvant Therapy for MelanomaPublished: May 3rd 2018 | Updated:
Dr. Tarhini on Recent Practice-Changing Clinical Trials in MelanomaPublished: August 21st 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5